-
- Union, Association, Cluster
Strong development with new records in revenues and investments in privately financed companies
Swiss Biotech Report 2026
– Revenue reached a new high of CHF 7.5 billion in 2025 (2024: CHF 7.2 billion), driven by more companies with market-ready products and sustained growing demand for specialized CDMO services.
– Capital inflows increased by 2.1% to CHF 2.6 billion. At the same time, the focus shifted significantly t…








